A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: A high placebo response

Teri Pearlstein, E. Spurell, L. A. Hohlstein, V. Gurney, J. Read, C. Fuchs, M. B. Keller

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty subjects with binge eating disorder were randomly assigned to flexible-dose fluvoxamine or placebo for 12 weeks. A significant reduction in binge frequency, Beck Depression Inventory scores and the eating concern, shape concern and weight concern subscales of the Eating Disorder Examination were noted for both fluvoxamine (n = 9) and placebo (n = 11) groups. There were no significant differences between fluvoxamine and placebo for any treatment outcome variables. The findings from this small trial contribute to the inconsistent results of antidepressant studies in binge eating disorder.

Original languageEnglish
Pages (from-to)147-151
Number of pages5
JournalArchives of Women's Mental Health
Volume6
Issue number2
DOIs
StatePublished - Apr 2003

Keywords

  • Binge eating disorder
  • Fluvoxamine
  • Placebo

Fingerprint

Dive into the research topics of 'A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: A high placebo response'. Together they form a unique fingerprint.

Cite this